The observation that this regulation depends on the cancer type, is further supported by the fact that p62 upregulation is central in promoting hepatocellular carcinoma (HCC) formation and resistance to therapies specifically through NRF2 activation [143,144]. Here, SQSTM1 is linked to hepatocellular carcinoma.